JCJoshua O. Cerasuolo

Joshua O. Cerasuolo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua O. Cerasuolo has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond physician headcounts: a population-based analysis of regional physician practice patterns in northern Ontario, Canada

    by Emilie Labranche, Sarah Newbery, Joshua O. Cerasuolo, Robert Ohle, David W. Savage

  • Open Access

    Role of Preoperative Abdominal MRI in Preventing Futile Laparotomy or Diagnostic Staging Laparoscopy in the Setting of Pancreatic Adenocarcinoma

    by Joshua O. Cerasuolo, Pablo E. Serrano, Noori Akhtar‐Danesh, Amer Alaref, David W. Savage, Joseph M. Caswell, Christian B. van der Pol

    Among patients with pancreatic cancer deemed resectable on computed tomography (CT), approximately 41% have more advanced disease that is not detected by CT. Diagnostic staging laparoscopy is used preoperatively either routinely or selectively in patients with high-risk features and may reduce unnecessary laparotomies by more than 20%. However, it remains an invasive procedure that requires general anesthesia and, when possible, should be avoided if metastatic disease is already evident on preoperative imaging. CT remains the standard imaging modality for staging pancreatic cancer and determining its resectability, but recent studies have demonstrated the added benefit of other radiological modalities in reducing unnecessary surgeries. Magnetic resonance imaging (MRI) is recommended for patients with high risk features to detect extra-pancreatic metastases or for those with indeterminate liver lesions on CT. Accordingly, at a population-level, we evaluated whether patients diagnosed with pancreatic adenocarcinoma and receiving preoperative abdominal MRI, in lieu of or combined with CT, had a lower likelihood of laparotomy and/or laparoscopy.

  • Open Access

    Development and Validation of the Predicting Risk of Ischemic Stroke in Malignancy Estimation Tool

    by Ronda Lun, Jenneke Leentjens, Joshua O. Cerasuolo, David Kirkwood, Moira K. Kapral, Marc Carrier, Deborah Siegal, Rinku Sutradhar

    Background: The risk of ischemic stroke is highest during the first year following a new diagnosis of cancer, but no tools exist to identify patients at highest risk. Methods: Using linked clinical and administrative databases, we conducted a population‐based retrospective cohort study of adults in Ontario, Canada, with newly diagnosed cancer from 2010 to 2021. Patients were randomly selected for prediction model derivation (60%) or validation (40%). The final model predicting ischemic stroke within 1 year following cancer diagnosis was derived using multivariable Fine‐Gray regression with candidate predictors selected via backward elimination. Subdistribution‐adjusted hazard ratios and 95% CIs were calculated, where all‐cause mortality was treated as a competing event. Performance of the prediction model was assessed in the validation cohort based on the C statistic and calibration plots for discrimination and calibration, respectively. Results: There were 698 566 eligible patients, with 418 911 in the derivation cohort and 279 576 in the validation cohort. The overall rate of stroke per 1000 person‐years was 6.7 (95% CI, 6.4–6.9). The final model included 22 predictors, including age, sex, demographic factors, cancer characteristics, and treatment characteristics. Discrimination was good, with a C statistic of 0.73. The model was well calibrated, with points following the desired 45‐degree line. Conclusions: We derived and validated the PRIME (Predicting Risk of Ischemic Stroke in Malignancy Estimation) tool with good discrimination for ischemic stroke in patients with a new cancer diagnosis. The model was built into an online calculator ( https://study.ohri.ca/PRIME/ ) and has the potential to stratify patients with cancer based on their risk of stroke within a year following their diagnosis.


  • Comparing outcomes of ureteric stent versus nephrostomy tube in urosepsis: a population-based study in Ontario, Canada

    by Hazem Elmansy, Mohamad Baker Berjaoui, David W. Savage, Joshua O. Cerasuolo, Tasneem Lalva, Rachel Mckay, Ahmed S. Zakaria

    Purpose Urolithiasis is a common cause of obstruction and sepsis requiring urgent urinary diversion via nephrostomy tubes (NT) or ureteric stents. This study compares all-cause mortality between patients treated with NT versus ureteric stents for urosepsis secondary to urolithiasis, both during hospitalization and within 90 days post-discharge. Methods We conducted a retrospective cohort study of adult patients hospitalized in Ontario, Canada, between April 2010 and December 2022, with an admitting diagnosis of urosepsis secondary to obstructive urolithiasis. Exclusion criteria included sepsis without concurrent urolithiasis, prior dialysis, end-stage renal disease, transplant, cystectomy, or genitourinary cancers. We used generalized linear and Cox regression models to compare all-cause mortality between NT and ureteric stent groups, applying inverse probability of treatment weighting (IPTW) to reduce selection bias. Our 90-day analysis also assessed the impact of definitive management following hospitalization. Results Among 4,573 patients, 620 underwent NT placement, and 3,953 received a ureteric stent. After adjusting for confounders, NT placement was associated with a 2.84-fold higher in-hospital mortality risk (RR: 2.84 [1.98, 3.92]) and a 1.52-fold higher 90-day mortality risk (HR: 1.52 [1.01, 2.30]). Furthermore, definitive management significantly reduced 90-day mortality risk by 62% (HR: 0.38 [0.23, 0.63]). Conclusion While both interventions aim to relieve obstruction and facilitate resolution of infection, NT placement is linked to higher in-hospital and 90-day mortality. These findings highlight the importance of treatment selection in optimizing patient outcomes.

  • Patterns of Survivorship Follow-Up Care Among Patients With Breast Cancer: A Retrospective Population-Based Cohort Study in Ontario, Canada, Between 2006 and 2016

    by Jonathan Sussman, Joshua O. Cerasuolo, Gregory R. Pond, Daryl Bainbridge, Hsien Seow

    PURPOSE: Many cancer survivors have ongoing follow-up with their oncologist(s), despite evidence that this care can be competently managed by primary care and transitioning well survivors could relieve growing pressure on cancer care systems. We analyzed population-based administrative data from Ontario, Canada, to examine rates of transition to primary care–led follow-up care during the survivorship phase, including clinical and demographic predictors associated with being transitioned. METHODS: We conducted a retrospective cohort study to describe the patterns of survivorship follow-up care among all patients with breast cancer in Ontario from 2006 to 2016. Data were derived from the Ontario Cancer Registry and other linked data sets. We defined the survivorship phase of care beginning at 2 years after initial diagnosis. Logistic regression was used to explore factors potentially prognostic of no oncology visits in each of the years after survivorship. RESULTS: Our survivorship cohort was composed of 71,719 patients with breast cancer, 42% of whom were considered to have transitioned from oncology to primary care 2 years after diagnosis. Although the number of patients having oncology visits diminished over time, a quarter of the cohort continued being seen in year 5 of survivorship. Regression analysis found older age, early cancer stage, living farther from a cancer center, not receiving radiation or chemotherapy, and high well-being to be associated with transitioning to primary care. CONCLUSION: Our findings contribute to the development of low-risk profiles among survivors to inform optimal transition from oncology to primary care. Further research examining qualitative perspectives from oncologists, cancer survivors, and primary care is also required to illuminate other sentinel factors to be considered when transitioning during follow-up.


  • Open Access

    Association of a Heart Failure Management Incentive in Primary Care With Clinical Outcomes: A Retrospective Cohort Study

    by Harsukh Benipal, Catherine Demers, Joshua O. Cerasuolo, Richard Perez, John J. You, Faizan Amin, Karim Keshavjee, Douglas S. Lee

    Background: We aim to examine the association between primary care physicians' billing of Q050A, a pay‐for‐performance heart failure (HF) management incentive fee code, and the composite outcome of mortality, hospitalization, and emergency department visits. Methods and Results: This population‐based cohort study linked administrative health databases in Ontario, Canada, for patients with HF aged >66 years between January 1, 2008, and March 31, 2020. Cases were patients with HF who had a Q050A fee code billed. Cases and controls were matched 1:1 on age, sex, patient status on being rostered to a primary care physician, cardiologist, or internist visit in the 6 months before study enrollment, Johns Hopkins Adjusted Clinical Group resource use bands, days between HF diagnosis and study enrollment (±2 years), and the logit of the propensity score. A Cox proportional hazards model assessed the association of Q050A with the outcome. A total of 59 664 cases had a Q050A billed, whereas 244 883 patients did not. Before matching, patients who had a Q050A billed were more likely to be men (52% versus 49%), were rostered to a primary care physician (100% versus 96%), had a higher Charlson Comorbidity Index, and had higher health care costs. The mean follow‐up was 481 days for cases and 530 days for controls. The composite outcome (hazard ratio, 1.11 [95% CI, 1.09–1.12]) was significantly higher for cases than controls. Conclusions: The Q050A incentive improved financial compensation for primary care physicians managing patients with HF but was not associated with improvements in the outcome. Research on promoting evidence‐based HF management is warranted.


  • Previous Ischemic Stroke Significantly Alters Stroke Risk in Newly Diagnosed Cancer Patients

    by Ronda Lun, Joshua O. Cerasuolo, Marc Carrier, Peter L. Gross, Moira K. Kapral, Michel Shamy, Dar Dowlatshahi, Rinku Sutradhar, Deborah M. Siegal

    BACKGROUND: Previous ischemic stroke (IS) is a risk factor for subsequent IS in the general population; it is unclear if this relationship remains true in patients with cancer. Our objective was to examine the association between previous IS and risk for future IS in individuals newly diagnosed with cancer. METHODS: We conducted a retrospective population-based matched cohort study of newly diagnosed adult cancer patients (excluding nonmelanoma skin cancers and primary central nervous system tumors) in Ontario, Canada from 2010 to 2020; those with prior IS were matched (1:4) by age, sex, year of cancer diagnosis, cancer stage, and cancer site to those without a history of stroke. Cumulative incidence function curves were created to estimate the incidence of IS. Subdistribution adjusted hazard ratios (aHRs) and 95% CIs were calculated, where death was treated as a competing event. Multivariable analysis was adjusted for imbalanced baseline characteristics. RESULTS: We examined 65 525 individuals with cancer, including 13 070 with a history of IS. The median follow-up duration was 743 days (interquartile range, 177–1729 days). The incidence of IS following cancer diagnosis was 261.3/10 000 person-years in the cohort with prior IS and 75.3/10 000 person-years in those without prior IS. Individuals with prior IS had an increased risk for IS after cancer diagnosis compared with those without a history (aHR, 2.68 [95% CI, 2.41–2.98]); they also had more prevalent cardiovascular risk factors. The highest risk for stroke compared with those without a history of IS was observed in the gynecologic cancer (aHR, 3.84 [95% CI, 2.15–6.85]) and lung cancer (aHR, 3.18 [95% CI, 2.52–4.02]) subgroups. The risk of IS was inversely correlated with lag time of previous stroke; those with IS 1 year before their cancer diagnosis had the highest risk (aHR, 3.68 [95% CI, 3.22–4.22]). CONCLUSIONS: Among individuals with newly diagnosed cancer, those with IS history were almost 3× more likely to experience a stroke after cancer diagnosis, especially if the prediagnosis stroke occurred within 1 year preceding cancer diagnosis.


  • Intravenous Thrombolysis After First-Ever Ischemic Stroke and Reduced Incident Dementia Rate

    by Joshua O. Cerasuolo, Jennifer Mandzia, Lauren E. Cipriano, Moira K. Kapral, Jiming Fang, Vladimir Hachinski, Luciano A. Sposato

    Background: The use of intravenous thrombolysis is associated with improved clinical outcomes. Whether thrombolysis is associated with reduced incidence of poststroke dementia remains uncertain. We sought to estimate if the use of thrombolysis following first-ever ischemic stroke was associated with a reduced rate of incident dementia using a pragmatic observational design. Methods: We included first-ever ischemic stroke patients from the Ontario Stroke Registry who had not previously been diagnosed with dementia. The primary outcome was incident dementia ascertained by a validated diagnostic algorithm. We employed inverse probability of treatment-weighted Cox proportional hazard models to estimate the cause-specific hazard ratio for the association of thrombolysis and incident dementia at 1 and 5 years following stroke. Results: From July 2003 to March 2013, 7072 patients with ischemic stroke were included, 3276 (46.3%) were female and mean age was 71.0 (SD, 12.8) years. Overall, 38.2% of the cohort (n=2705) received thrombolysis, 77.2% (n=2087) of which was administered within 3 hours of stroke onset. In the first year following stroke, thrombolysis administration was associated with a 24% relative reduction in the rate of developing dementia (cause-specific hazard ratio, 0.76 [95% CI, 0.58–0.97]). This association remained significant at 5 years (cause-specific hazard ratio, 0.79 [95% CI, 0.66–0.91]) and at the end of follow-up (median 6.3 years; cause-specific hazard ratio, 0.79 [95% CI, 0.68–0.89]). Conclusions: Thrombolysis administration following first-ever ischemic stroke was independently associated with a reduced rate of dementia. Incident dementia should be considered as a relevant outcome when evaluating risk/benefit of thrombolysis in ischemic stroke patients.


  • Open Access

    Diagnostic Performance of Serial High-Sensitivity Cardiac Troponin Measurements in the Emergency Setting

    by Peter A. Kavsak, Mark K. Hewitt, Shawn E. Mondoux, Joshua O. Cerasuolo, Jinhui Ma, Natasha Clayton, Matthew McQueen, Lauren E. Griffith, Richard Perez, Hsien Seow, et al.

    Serial high-sensitivity cardiac troponin (hsTn) testing in the emergency department (ED) and the intensive cardiac care unit may assist physicians in ruling out or ruling in acute myocardial infarction (MI). There are three major algorithms proposed for high-sensitivity cardiac troponin I (hsTnI) using serial measurements while incorporating absolute concentration changes for MI or death following ED presentation. We sought to determine the diagnostic estimates of these three algorithms and if one was superior in two different Canadian ED patient cohorts with serial hsTnI measurements. An undifferentiated ED population (Cohort-1) and an ED population with symptoms suggestive of acute coronary syndrome (ACS; Cohort-2) were clinically managed with non-hsTn testing with the hsTnI testing performed in real-time with physicians blinded to these results (i.e., hsTnI not reported). The three algorithms evaluated were the European Society of Cardiology (ESC), the High-STEACS pathway, and the COMPASS-MI algorithm. The diagnostic estimates were derived for each algorithm for the 30-day MI/death outcome for the rule-out and rule-in arm in each cohort and compared to proposed diagnostic benchmarks (i.e., sensitivity ≥ 99.0% and specificity ≥ 90.0%) with 95% confidence intervals (CI). In Cohort-1 (n = 2966 patients, 15.3% had outcome) and Cohort-2 (n = 935 patients, 15.6% had outcome), the algorithm that obtained the highest sensitivity (97.8%; 95% CI: 96.0–98.9 and 98.6%; 95% CI: 95.1–99.8, respectively) in both cohorts was COMPASS-MI. Only Cohort-2 with both the ESC and COMPASS-MI algorithms exceeded the specificity benchmark (97.0%; 95% CI: 95.5–98.0 and 96.7%; 95% CI: 95.2–97.8, respectively). Patient selection for serial hsTnI testing will affect specificity estimates, with no algorithm achieving a sensitivity ≥ 99% for 30-day MI or death.


  • Open Access

    Risk Stratification for Patients with Chest Pain Discharged Home from the Emergency Department

    by Peter A. Kavsak, Joshua O. Cerasuolo, Shawn E. Mondoux, Jonathan Sherbino, Jinhui Ma, Brock K. Hoard, Richard Perez, Hsien Seow, Dennis T. Ko, Andrew Worster

    For patients with chest pain who are deemed clinically to be low risk and discharged home from the emergency department (ED), it is unclear whether further laboratory tests can improve risk stratification. Here, we investigated the utility of a clinical chemistry score (CCS), which comprises plasma glucose, the estimated glomerular filtration rate, and high-sensitivity cardiac troponin (I or T) to generate a common score for risk stratification. In a cohort of 14,676 chest pain patients in the province of Ontario, Canada and who were discharged home from the ED (November 2012–February 2013 and April 2013–September 2015) we evaluated the CCS as a risk stratification tool for all-cause mortality, plus hospitalization for myocardial infarction or unstable angina (primary outcome) at 30, 90, and 365 days post-discharge using Cox proportional hazard models. At 30 days the primary outcome occurred in 0.3% of patients with a CCS < 2 (n = 6404), 0.9% of patients with a CCS = 2 (n = 4336), and 2.3% of patients with a CCS > 2 (n = 3936) (p < 0.001). At 90 days, patients with CCS < 2 (median age = 52y (IQR = 46–60), 59.4% female) had an adjusted HR = 0.51 (95% confidence interval (CI) = 0.32–0.82) for the composite outcome and patients with a CCS > 2 (median age = 74y (IQR = 64–82), 48.0% female) had an adjusted HR = 2.80 (95%CI = 1.98–3.97). At 365 days, 1.3%, 3.4%, and 11.1% of patients with a CCS < 2, 2, or >2 respectively, had the composite outcome (p < 0.001). In conclusion, the CCS can risk stratify chest pain patients discharged home from the ED and identifies both low- and high-risk patients who may warrant different medical care.